{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:36:06Z","timestamp":1766054166846,"version":"3.48.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["No. 2018ZX09301007005"],"award-info":[{"award-number":["No. 2018ZX09301007005"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40262-025-01584-3","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T05:48:54Z","timestamp":1760680134000},"page":"1897-1907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Pharmacodynamics, and Safety of Olorigliflozin in Individuals with Type 2 Diabetes Mellitus with or without Renal Impairment: A Single-Center, Single-Dose, Open-Label Trial"],"prefix":"10.1007","volume":"64","author":[{"given":"Man","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kang","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchun","family":"Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huifang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuangqing","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheng","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guannan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenmei","family":"An","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5488-0814","authenticated-orcid":false,"given":"Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"8","key":"1584_CR1","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.3390\/molecules25081987","volume":"25","author":"A Artasensi","year":"2020","unstructured":"Artasensi A, Pedretti A, Vistoli G, Fumagalli L. Type 2 diabetes mellitus: a review of multi-target drugs. Molecules. 2020;25(8):1987.","journal-title":"Molecules"},{"issue":"Suppl. 1","key":"1584_CR2","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.2337\/dc23-S002","volume":"46","author":"NA ElSayed","year":"2023","unstructured":"ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, Bruemmer D, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(Suppl. 1):S19\u201340.","journal-title":"Diabetes Care"},{"issue":"2","key":"1584_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.2337\/dbi18-0007","volume":"68","author":"RZ Alicic","year":"2019","unstructured":"Alicic RZ, Neumiller JJ, Johnson EJ, Dieter B, Tuttle KR. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes. 2019;68(2):248\u201357.","journal-title":"Diabetes"},{"issue":"1","key":"1584_CR4","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","volume":"19","author":"L Ni","year":"2020","unstructured":"Ni L, Yuan C, Chen G, Zhang C, Wu X. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol. 2020;19(1):98.","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"1584_CR5","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","volume":"42","author":"M Griffin","year":"2020","unstructured":"Griffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020;42(11):1028\u201339.","journal-title":"Circulation"},{"issue":"7","key":"1584_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644\u201357.","journal-title":"N Engl J Med"},{"issue":"22","key":"1584_CR7","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1161\/CIRCULATIONAHA.119.040130","volume":"139","author":"ET Kato","year":"2019","unstructured":"Kato ET, Silverman MG, Mosenzon O, Zelniker TA, Cahn A, Furtado RHM, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019;139(22):2528\u201336.","journal-title":"Circulation"},{"issue":"12","key":"1584_CR8","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S2213-8587(21)00240-0","volume":"9","author":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC)","year":"2021","unstructured":"Global Health & Population Project on Access to Care for Cardiometabolic Diseases (HPACC). Expanding access to newer medicines for people with type 2 diabetes in low-income and middle-income countries: a cost-effectiveness and price target analysis. Lancet Diabetes Endocrinol. 2021;9(12):825\u201336.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1584_CR9","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/dom.13887","volume":"22","author":"H Zhang","year":"2020","unstructured":"Zhang H, Zhu X, Li X, Chen H, Wu M, Li C, et al. Pharmacokinetics and pharmacodynamics of rongliflozin, a novel selective inhibitor of sodium-glucose co-transporter-2, in people with type 2 diabetes mellitus. Diabetes Obes Metab. 2020;22(2):191\u2013202.","journal-title":"Diabetes Obes Metab"},{"issue":"17","key":"1584_CR10","doi-asserted-by":"publisher","first-page":"6355","DOI":"10.1021\/jm100332n","volume":"53","author":"S Nomura","year":"2010","unstructured":"Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, et al. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J Med Chem. 2010;53(17):6355\u201360.","journal-title":"J Med Chem"},{"issue":"5","key":"1584_CR11","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/j.clinthera.2020.03.007","volume":"42","author":"H Zhang","year":"2020","unstructured":"Zhang H, Liu J, Zhu X, Li X, Chen H, Wu M, et al. A phase I study on the pharmacokinetics and pharmacodynamics of DJT1116PG, a novel selective inhibitor of sodium-glucose cotransporter type 2, in healthy individuals at steady state. Clin Ther. 2020;42(5):892-905.e893.","journal-title":"Clin Ther"},{"issue":"4","key":"1584_CR12","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.cmet.2021.02.016","volume":"33","author":"T Sen","year":"2021","unstructured":"Sen T, Heerspink HJL. A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors. Cell Metab. 2021;33(4):732\u20139.","journal-title":"Cell Metab"},{"issue":"1","key":"1584_CR13","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S0254-6272(15)30003-0","volume":"35","author":"G Yang","year":"2015","unstructured":"Yang G, Zhang M, Zhang M, Chen S, Chen P. Effect of Huangshukuihua (Flos Abelmoschi manihot) on diabetic nephropathy: a meta-analysis. J Tradit Chin Med. 2015;35(1):15\u201320.","journal-title":"J Tradit Chin Med"},{"unstructured":"National Center for Chronic Disease Prevention and Health Promotion (U.S.). Division of Diabetes Translation. National diabetes statistics report, 2020: estimates of diabetes and its burden in the United States. https:\/\/stacks.cdc.gov\/view\/cdc\/85309. Accessed 2025 May 10.","key":"1584_CR14"},{"key":"1584_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000324934","volume":"170","author":"AT Reutens","year":"2011","unstructured":"Reutens AT, Atkins RC. Epidemiology of diabetic nephropathy. Contrib Nephrol. 2011;170:1\u20137.","journal-title":"Contrib Nephrol"},{"unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH Harmonised Guideline: Guideline for Good Clinical Practice. E6(R3). 2025. https:\/\/database.ich.org\/sites\/default\/files\/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf. Accessed 2025 May 10.","key":"1584_CR16"},{"unstructured":"Chinese Diabetes Society. National guidelines for the prevention and control of type 2 diabetes in China 2020. https:\/\/diab.cma.org.cn\/cn\/zhinangongshi.aspx. Accessed 2025 May 10.","key":"1584_CR17"},{"unstructured":"European Medicines Agency (EMA). Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function. London: EMA; 2015. https:\/\/www.ema.europa.eu\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf. Accessed 2025 May 10.","key":"1584_CR18"},{"unstructured":"US Department of Health and Human Services; Food and Drug Administration; Center for Drug Evaluation and Research (CDER). Pharmacokinetics in patients with impaired renal function\u2014study design, data analysis, and impact on dosing. Guidance for industry. 2024. https:\/\/www.fda.gov\/media\/78573\/download. Accessed 2025 May 10.","key":"1584_CR19"},{"issue":"4","key":"1584_CR20","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145(4):247\u201354.","journal-title":"Ann Intern Med"},{"unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH harmonised guideline: Bioanalytical method validation and study sample analysis. M10. 2022. https:\/\/database.ich.org\/sites\/default\/files\/M10_Guideline_Step4_2022_0524.pdf. Accessed 2025 May 10.","key":"1584_CR21"},{"issue":"4","key":"1584_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/s19040800","volume":"19","author":"W Villena Gonzales","year":"2019","unstructured":"Villena Gonzales W, Mobashsher AT, Abbosh A. The progress of glucose monitoring\u2014a review of invasive to minimally and non-invasive techniques, devices and sensors. Sensors. 2019;19(4):800.","journal-title":"Sensors"},{"unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. Medical Dictionary for Regulatory Activities (MedDRA). Version 26.0 2023. https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/intguide_26_0_English.pdf. Accessed 2025 May 10.","key":"1584_CR23"},{"unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0 2017. https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50. Accessed 2025 May 10.","key":"1584_CR24"},{"issue":"9","key":"1584_CR25","doi-asserted-by":"publisher","first-page":"1960","DOI":"10.1016\/j.biochi.2012.05.017","volume":"94","author":"J Baraka-Vidot","year":"2012","unstructured":"Baraka-Vidot J, Guerin-Dubourg A, Bourdon E, Rondeau P. Impaired drug-binding capacities of in vitro and in vivo glycated albumin. Biochimie. 2012;94(9):1960\u20137.","journal-title":"Biochimie"},{"issue":"7","key":"1584_CR26","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1681\/ASN.V1271549","volume":"12","author":"GA Kaysen","year":"2001","unstructured":"Kaysen GA. The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol. 2001;12(7):1549\u201357.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"1584_CR27","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1038\/ki.1987.151","volume":"31","author":"GA Kaysen","year":"1987","unstructured":"Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int. 1987;31(6):1368\u201376.","journal-title":"Kidney Int"},{"issue":"6","key":"1584_CR28","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.dsx.2018.06.003","volume":"12","author":"V Tsimihodimos","year":"2018","unstructured":"Tsimihodimos V, Filippatos TD, Elisaf MS. SGLT2 inhibitors and the kidney: effects and mechanisms. Diabetes Metab Syndr. 2018;12(6):1117\u201323.","journal-title":"Diabetes Metab Syndr"},{"key":"1584_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.814074","volume":"12","author":"S Hu","year":"2022","unstructured":"Hu S, Lin C, Cai X, Zhu X, Lv F, Nie L, et al. The urinary glucose excretion by sodium-glucose cotransporter 2 inhibitor in patients with different levels of renal function: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;12:814074.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1584_CR30","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1111\/j.1463-1326.2011.01359.x","volume":"13","author":"S Kasichayanula","year":"2011","unstructured":"Kasichayanula S, Chang M, Hasegawa M, Liu X, Yamahira N, LaCreta FP, et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes Metab. 2011;13(4):357\u201365.","journal-title":"Diabetes Obes Metab"},{"issue":"24","key":"1584_CR31","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295\u2013306.","journal-title":"N Engl J Med"},{"issue":"1","key":"1584_CR32","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/S2213-8587(20)30369-7","volume":"9","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, Hou FF, et al. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol. 2021;9(1):22\u201331.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"1584_CR33","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","volume":"7","author":"O Mosenzon","year":"2019","unstructured":"Mosenzon O, Wiviott SD, Cahn A, Rozenberg A, Yanuv I, Goodrich EL, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1584_CR34","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"WG Herrington","year":"2023","unstructured":"Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117\u201327.","journal-title":"N Engl J Med"},{"issue":"12","key":"1584_CR35","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/s41569-020-0406-8","volume":"17","author":"MR Cowie","year":"2020","unstructured":"Cowie MR, Fisher M. SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol. 2020;17(12):761\u201372.","journal-title":"Nat Rev Cardiol"},{"issue":"3","key":"1584_CR36","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/dmrr.2479","volume":"30","author":"M Zhang","year":"2014","unstructured":"Zhang M, Zhang L, Wu B, Song H, An Z, Li S. Dapagliflozin treatment for type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2014;30(3):204\u201321.","journal-title":"Diabetes Metab Res Rev"},{"issue":"3","key":"1584_CR37","doi-asserted-by":"publisher","first-page":"325","DOI":"10.4103\/0019-5049.115608","volume":"57","author":"S Parida","year":"2013","unstructured":"Parida S. Clinical causality assessment for adverse drug reactions. Indian J Anaesth. 2013;57(3):325\u20136.","journal-title":"Indian J Anaesth"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-025-01584-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-025-01584-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T10:32:39Z","timestamp":1766053959000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-025-01584-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":37,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1584"],"URL":"https:\/\/doi.org\/10.1007\/s40262-025-01584-3","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"type":"print","value":"0312-5963"},{"type":"electronic","value":"1179-1926"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"15 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yingjun Zhang serves as Chairman of Sunshine Lake Pharma Co., Ltd., and Zheng Gu, Guannan Wang, Wentao Guo, and Lin Luo hold employee positions at the organization. Man Chen, Xiaotao Cao, Kang An, Ying Wang, Qiao Yan, Yuchun Men, Huifang Wang, Miao He, Shuangqing Du, Zhenmei An, and Ping Feng have no potential conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Man Chen: methodology, formal analysis, visualization, writing\u2014original draft, writing\u2014review, and editing. Xiaotao Cao: methodology, visualization, writing\u2014review, and editing. An Kang: project administration and supervision. Ying Wang, Qiao Yan, Yuchun Men, Huifang Wang, Miao He, and Shuangqing Du: project administration, data acquisition, and data curation. Zheng Gu: project administration. Yingjun Zhang: Conceptualization, writing\u2014review, and editing. Guannan Wang, Wentao Guo, and Lin Luo: data curation and data analysis. Zhenmei An and Ping Feng: conceptualization, formal analysis, investigation, methodology, writing\u2014review, and editing.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"The trial was approved by the China Food and Drug Administration (approval 2016L03679) and the Independent Ethics Committee of West China Hospital (2021 Clinical Trial [Western Medicine] Review 236).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All participants signed written informed consent before enrollment.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}